Mintz Guides QIAGEN In Its $150 Million Purchase Of Verogen
BOSTON – Mintz has served as legal counsel to long-standing client QIAGEN N.V. in its $150 million completed acquisition of Verogen, a leader in the use of next-generation sequencing technologies to drive the future of human identification and forensic investigation.
QIAGEN is a Netherlands based company that provides the technology to isolate and process DNA, RNA and proteins from blood, tissue and other material samples. QIAGEN and Verogen have been commercialization partners since June 2021.
The Mintz team acting for QIAGEN included Members Daniel Follansbee and Jonathan Kravetz, and Associate Wuqi Liu.
Mintz, a leading life sciences law firm, represents therapeutics, vaccine, medical device and systems, research tools and diagnostics companies, as well as investment banks, venture capital firms and other investors. Our work for these clients encompasses transactional, health care regulatory, intellectual property, litigation, employment, real estate and other matters. We are embedded in the global life sciences ecosystem and provide industry leaders with practical solutions to business-critical challenges, helping them achieve their strategic and business goals.
- $22B+ in transactions handled in 2021 for industry clients, including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings
- Advise on the complete spectrum of FDA regulations, from clinical trials through product launch and beyond, including product approvals, labeling, and supply and distribution agreements
- Prosecute patents to issuance (more than 30 patent team members have biology or chemistry PhDs), navigate trademarks through the USPTO and health regulatory bodies, and defend patent, trade secret and trademark rights in trial courts and at the USPTO
Successful track record of helping life sciences clients avoid — and when necessary resolve —securities class actions, governmental investigations, and disputes with collaboration/licensing partners